Remicade (infliximab) is a medication used to treat Crohn’s disease, ulcerative colitis and rheumatoid arthritis. For Crohn’s disease, Remicade can help in decreasing symptoms and achieving remission in patients who have not adequately responded to other medical therapies. For those who suffer from ulcerative colitis or rheumatoid arthritis, Remicade can help decrease the inflammation associated with those conditions.
Remicade is given by infusion, which means it is a medicine that is injected directly into the vein. This procedure may take 2.5 to 3 hours, and is done in DDA’s Infusion Center in Annapolis. When patients begin receiving treatment with Remicade, they usually are prescribed treatments at two weeks and six weeks after the first infusion. After that initial treatment, infusions are typically given in eight week intervals.
Acute reactions (less than 24 hours after infusion)
During the infusion some patients may experience a reaction. Symptoms include fever, chest pain, heart palpitations, sweating, nausea, flushing, itching, changes in blood pressure and difficulty breathing. These reactions usually go away by slowing the rate of infusion or taking acetaminophen, antihistamines, steroids and/or epinephrine. Your physician may recommend specific medications prior to your next infusion to decrease your possibility of having another reaction.
Delayed reactions (24 hours to 14 days after infusion)
A reaction can occur after the infusion is completed. Symptoms generally include muscle or joint aches, itching, rash, fever and fatigue, and can be relieved by taking acetaminophen, antihistamines and steroids. If you experience these symptoms after your infusion, your physician may recommend specific medications prior to your next infusion to decrease your possibility of having a delayed reaction
The DDA Remicade Infusion Center is open for appointments Tuesday and Thursday from 8am to 4pm.
To schedule an appointment, please call 410-224-4887 ext. 404.